Focal Therapy for Prostate Cancer: Complications and Their Treatment.

HIFU complications cryotherapy focal therapy photodynamic therapy prostate cancer

Journal

Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127

Informations de publication

Date de publication:
2021
Historique:
received: 16 04 2021
accepted: 21 06 2021
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 30 7 2021
Statut: epublish

Résumé

Focal therapy is a modern alternative to selectively treat a specific part of the prostate harboring clinically significant disease while preserving the rest of the gland. The aim of this therapeutic approach is to retain the oncological benefit of active treatment and to minimize the side-effects of common radical treatments. The oncological effectiveness of focal therapy is yet to be proven in long-term robust trials. In contrast, the toxicity profile is well-established in randomized controlled trials and multiple robust prospective cohort studies. This narrative review summarizes the relevant evidence on complications and their management after focal therapy. When compared to whole gland treatments, focal therapy provides a substantial benefit in terms of adverse events reduction and preservation of genito-urinary function. The most common complications occur in the peri-operative period. Urinary tract infection and acute urinary retention can occur in up to 17% of patients, while dysuria and haematuria are more common. Urinary incontinence following focal therapy is very rare (0-5%), and the vast majority of patients recover in few weeks. Erectile dysfunction can occur after focal therapy in 0-46%: the baseline function and the ablation template are the most important factors predicting post-operative erectile dysfunction. Focal therapy in the salvage setting after external beam radiotherapy has a significantly higher rate of complications. Up to one man in 10 will present a severe complication.

Identifiants

pubmed: 34322516
doi: 10.3389/fsurg.2021.696242
pmc: PMC8311122
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

696242

Informations de copyright

Copyright © 2021 Rakauskas, Marra, Heidegger, Kasivisvanathan, Kretschmer, Zattoni, Preisser, Tilki, Tsaur, van den Bergh, Kesch, Ceci, Fankhauser, Gandaglia and Valerio.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a shared affiliation, though no other collaboration, with one of the authors FP at the time of the review.

Références

J Endourol. 2015 Jun;29(6):640-9
pubmed: 25335575
Health Technol Assess. 2018 Sep;22(52):1-96
pubmed: 30264692
Eur Urol. 2016 May;69(5):844-51
pubmed: 26525837
Lancet Oncol. 2012 Jun;13(6):622-32
pubmed: 22512844
Urol Oncol. 2018 Feb;36(2):67-76
pubmed: 29277585
N Engl J Med. 2013 Jan 31;368(5):436-45
pubmed: 23363497
J Urol. 2017 Feb;197(2):320-326
pubmed: 27484386
Eur Urol. 2016 Jun;69(6):973-5
pubmed: 26778462
J Endourol. 2019 Jul;33(7):509-515
pubmed: 31017001
Urol Int. 2020;104(5-6):378-385
pubmed: 32396911
Curr Opin Urol. 2014 May;24(3):218-24
pubmed: 24637316
Eur Urol. 2019 Jul;76(1):98-105
pubmed: 30638633
Urol Oncol. 2020 Apr;38(4):225-230
pubmed: 31628038
Eur Urol. 2020 Sep;78(3):371-378
pubmed: 32532513
J Urol. 2021 Jan;205(1):129-136
pubmed: 33119421
Transl Androl Urol. 2020 Apr;9(2):332-343
pubmed: 32420139
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Eur Urol. 2014 Oct;66(4):732-51
pubmed: 23769825
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Prostate Int. 2020 Jun;8(2):85-90
pubmed: 32647645
J Urol. 2015 Aug;194(2):364-70
pubmed: 25711199
Br J Cancer. 2017 Apr 25;116(9):1159-1165
pubmed: 28350785
Eur Urol Oncol. 2021 Jun;4(3):405-423
pubmed: 33423943
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299
pubmed: 28349978
BJU Int. 2018 May;121(5):676-677
pubmed: 29687953
J Urol. 2021 Feb;205(2):444-451
pubmed: 33026934
BMJ Open. 2020 Dec 15;10(12):e045500
pubmed: 33323452
Med Sci (Basel). 2019 Dec 10;7(12):
pubmed: 31835522
Eur Urol. 2018 Oct;74(4):422-429
pubmed: 29960750
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Transl Androl Urol. 2020 Jun;9(3):1535-1545
pubmed: 32676441
Lancet Oncol. 2017 Feb;18(2):181-191
pubmed: 28007457
Eur Urol. 2015 Apr;67(4):771-7
pubmed: 25281389
Future Oncol. 2017 Apr;13(8):727-741
pubmed: 27882770
Eur Urol. 2015 Dec;68(6):927-36
pubmed: 25682339

Auteurs

Arnas Rakauskas (A)

Department of Urology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Giancarlo Marra (G)

Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.

Isabel Heidegger (I)

Department of Urology, Medical University Innsbruck, Innsbruck, Austria.

Veeru Kasivisvanathan (V)

Division of Surgery and Interventional Science, University College London, London, United Kingdom.
Department of Urology, University College London Hospital, London, United Kingdom.

Alexander Kretschmer (A)

Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany.

Fabio Zattoni (F)

Urology Unit, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.

Felix Preisser (F)

Department of Urology, University Hospital Frankfurt, Frankfurt, Germany.

Derya Tilki (D)

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Igor Tsaur (I)

Department of Urology and Pediatric Urology, Mainz University Medicine, Mainz, Germany.

Roderick van den Bergh (R)

Department of Urology, Antonius Hospital, Utrecht, Netherlands.

Claudia Kesch (C)

Department of Urology, University Hospital Essen, Essen, Germany.

Francesco Ceci (F)

Division of Nuclear Medicine, IEO European Institute of Oncology Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.

Christian Fankhauser (C)

Department of Urology, University Hospital Zürich, Zurich, Switzerland.

Giorgio Gandaglia (G)

Division of Oncology/Unit of Urology, Urological Research Institute, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) Ospedale San Raffaele, Milan, Italy.

Massimo Valerio (M)

Department of Urology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Classifications MeSH